Leidos (LDOS) Q4 2025 earnings review
Profit Powerhouse Masked by Top-Line Noise
Leidos delivered a complex Q4: headline revenue fell 4% due to a calendar comparison (extra week in prior year) and a government shutdown, yet profitability surged. Adjusted EPS grew 16% to $2.76, and Adjusted EBITDA margin expanded 160bps to 13.2%. While the operational core remains efficient, the Health & Civil segment—previously a growth engine—contracted 9%. The narrative shifts significantly with the $2.4B acquisition of Entrust, betting big on energy infrastructure, alongside a segment restructuring for FY26.
🐂 Bull Case
Despite revenue headwinds, Leidos maintained a 13.2% Adjusted EBITDA margin in Q4 and hit a record 14.1% for the full year. Operational discipline is offsetting volume volatility.
Operating cash flow hit a Q4 record of $495M. With FY25 Free Cash Flow up 26% to $1.63B (104% conversion), the balance sheet is primed to digest the Entrust acquisition.
🐻 Bear Case
The Health & Civil segment, a consistent driver throughout FY24/25, saw revenues drop 9% YoY in Q4. While margins held, the volume decline signals a potential peak in the managed health services surge.
FY26 guidance calls for 'Mid 13%' Adjusted EBITDA margins. Compared to the 14.1% achieved in FY25, this represents a meaningful deceleration in profitability, likely due to investment needs or mix shifts.
⚖️ Verdict: 🟢
Bullish. The revenue decline is largely technical (calendar/shutdown), while the earnings power is real. The Entrust acquisition aligns with secular energy trends. However, the guided margin compression for FY26 warrants close monitoring.
Key Themes
Defense Systems Profitability Recovery
A massive turnaround story in the Defense Systems segment. After struggling with a 0.4% margin in the prior year period (due to write-downs and ramp costs), margins exploded to 8.1% (GAAP) and 10.3% (Non-GAAP) in Q4. This segment has transitioned from a drag on earnings to a contributor, driven by 'rigorous cost-discipline' and production maturation.
Health & Civil Growth Stalls
After quarters of propelling the company forward, Health & Civil revenue fell 9% YoY to $1.21B. Management cited the 'managed health services business' as a headwind—a sharp reversal from previous quarters where high volumes in this specific area drove beats. Despite the drop, margins remained elite at 21.9%, but the volume loss is a red flag for future growth.
Entrust Acquisition & Energy Pivot
Leidos announced the $2.4B acquisition of Entrust to anchor its energy infrastructure strategy. This moves the company deeper into the utility value chain (generation, transmission, distribution) rather than just services. This aligns with the 'NorthStar 2030' strategy but introduces integration risk and leverage.
Backlog & Bookings Strength
Net bookings of $5.6B in Q4 (1.3x book-to-bill) pushed backlog to a record $49.0B. Notable wins in missile defense (ABADS-MD, $2.2B) and Air Force cloud (C1N, $455M) validate the 'solution-provider' strategy over simple staff augmentation.
Fiscal 2026 Margin Reset
Management guided FY26 Adjusted EBITDA margins to 'Mid 13%'. While healthy, this is a step down from the 14.1% delivered in FY25. This suggests FY25 may have been 'over-earning' due to specific program efficiencies or one-offs that will not repeat, or that the Entrust integration will dilute margins initially.
Other KPIs
Accelerating. Up from 12.9% in FY24. Driven by Health & Civil performance and fixed-price program efficiencies. However, guidance suggests this metric reverses slightly in FY26.
Accelerating. Up 26% YoY. Free cash flow conversion remained robust at 104%. Operating cash flow of $1.75B underscores the high quality of earnings.
Decelerating. Down 3% YoY. While impacted by the extra week comp, this segment remains the largest revenue contributor. The backlog here remains strong with new classified wins.
Guidance
Stable. Implies ~2% to 4% growth over FY25's $17.17B. This is relatively modest organic growth, suggesting the company is prioritizing margin and mix over pure top-line expansion.
Decelerating. This is a drop from the 14.1% achieved in FY25. Management notes difficult comps and potential mix shifts. It signals that FY25's margin profile was exceptional rather than the new baseline.
Stable. At the midpoint ($12.25), this represents only ~2% growth over FY25's $11.99. This low growth rate relative to revenue suggests headwinds from interest expense (Entrust debt) or tax rates.
Stable. Consistent with FY25 results ($1.75B). Indicates that cash generation remains a priority and is not expected to degrade despite the integration of new assets.
Key Questions
Health & Civil Volume Drop
Revenues in Health & Civil dropped 9% in Q4. Was this purely due to the calendar week/shutdown, or has the volume of medical disability exams structurally peaked?
Margin Step-Down Logic
FY25 EBITDA margin was 14.1%, but FY26 guidance is 'Mid 13%'. What specific factors (Entrust mix, investment spend, contract roll-offs) are driving this ~60-100bps compression?
Entrust Integration & Leverage
With $2.4B allocated to Entrust, how does this impact the timeline for share repurchases in FY26? What is the expected leverage ratio post-close?